Daclatasvir dihydrochloride/Asunaprevir/Beclabuvir hydrochloride

N/A

Report date: 2023/04/13 17:56:07

Base Information

Drug NameDaclatasvir dihydrochloride/Asunaprevir/Beclabuvir hydrochloride
Drug Alias Name盐酸达拉他韦/阿舒瑞韦/盐酸贝卡布韦Ximency
ClassificationSmall molecules
Mechanisms of ActionNonstructural protein 5A inhibitorsHepatitis C virus NS5B RNA-dependent RNA polymerase inhibitorsHepatitis C virus serine protease, NS3/NS4A inhibitors
TargetsHepatitis C virus NS5B RNA-dependent RNA polymeraseNonstructural protein 5AHepatitis C virus serine protease, NS3/NS4A
Therapy Area/IndicationsFibrosisHepatitis C
Global Approved IndicationsFibrosisHepatitis C
Approved Indications in ChinaN/A
Original Approved Country/TerritoryJapan
Original Approved Date2016/12/19
Country/TerritoryCanadaUnited StatesTaiwan +[9] 
CombinationsYes AsunaprevirDaclatasvir DihydrochlorideBeclabuvir hydrochloride
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesBristol-Myers Squibb Company
China Registration ClassN/A

Develop Information

Active CompaniesBristol-Myers Squibb Company
Inactive CompaniesBristol Myers Squibb Srlcompany
Active IndicationsFibrosisHepatitis C
Inactive IndicationsN/A

Other Information

ATC CodeJ05AP58
Related LinksKEGG